![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine/tenofovir in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE)
|
|
|
Reported by Jules Levin
18th Intl AIDS Conference July 18-23 Vienna Austria
J. Gathe, JR. Bogner, S. Santiago, A. Horban, M. Nelson, P. Cahn, J. Andrade, D. Spencer, C. Yong, T. Nguyen, W. Zhang, M. Drulak and A. Quinson*
*Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA
![](../images/072210/072210-12/image002.gif)
![](../images/072210/072210-12/image004.gif)
![](../images/072210/072210-12/image006.gif)
![](../images/072210/072210-12/image008.gif)
![](../images/072210/072210-12/image010.gif)
![](../images/072210/072210-12/image012.gif)
![](../images/072210/072210-12/image014.gif)
![](../images/072210/072210-12/image016.gif)
![](../images/072210/072210-12/image018.gif)
![](../images/072210/072210-12/image020.gif)
![](../images/072210/072210-12/image022.gif)
![](../images/072210/072210-12/image024.gif)
![](../images/072210/072210-12/image026.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|